STEVANATO GROUP SPA O.N. (87N) - Net Assets
Based on the latest financial reports, STEVANATO GROUP SPA O.N. (87N) has net assets worth €1.53 Billion EUR (≈ $1.79 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.58 Billion ≈ $3.02 Billion USD) and total liabilities (€1.05 Billion ≈ $1.23 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of STEVANATO GROUP SPA O.N. for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.53 Billion |
| % of Total Assets | 59.25% |
| Annual Growth Rate | 15.28% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 6.64 |
STEVANATO GROUP SPA O.N. - Net Assets Trend (2021–2025)
This chart illustrates how STEVANATO GROUP SPA O.N.'s net assets have evolved over time, based on quarterly financial data. Check STEVANATO GROUP SPA O.N. (87N) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for STEVANATO GROUP SPA O.N. (2021–2025)
The table below shows the annual net assets of STEVANATO GROUP SPA O.N. from 2021 to 2025. For live valuation and market cap data, see 87N market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.49 Billion ≈ $1.74 Billion |
+5.85% |
| 2024-12-31 | €1.40 Billion ≈ $1.64 Billion |
+23.99% |
| 2023-12-31 | €1.13 Billion ≈ $1.32 Billion |
+13.73% |
| 2022-12-31 | €995.91 Million ≈ $1.16 Billion |
+18.33% |
| 2021-12-31 | €841.66 Million ≈ $983.99 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to STEVANATO GROUP SPA O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 99042700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €990.43 Million | 66.63% |
| Other Components | €496.06 Million | 33.37% |
| Total Equity | €1.49 Billion | 100.00% |
STEVANATO GROUP SPA O.N. Competitors by Market Cap
The table below lists competitors of STEVANATO GROUP SPA O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Penguin Solutions, Inc.
NASDAQ:PENG
|
$1.01 Billion |
|
Bank Tabungan Negara Persero
JK:BBTN
|
$1.01 Billion |
|
Sichuan Xunyou Network Technology Co Ltd
SHE:300467
|
$1.01 Billion |
|
Der International Home Furnishing Co Ltd
SHE:002631
|
$1.01 Billion |
|
SeAH Bestee
KO:001430
|
$1.01 Billion |
|
Altamir SCA
PA:LTA
|
$1.01 Billion |
|
CRA International Inc
NASDAQ:CRAI
|
$1.01 Billion |
|
Suzhou Keda Technology Co Ltd
SHG:603660
|
$1.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in STEVANATO GROUP SPA O.N.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,404,339,000 to 1,486,483,000, a change of 82,144,000 (5.8%).
- Net income of 139,839,000 contributed positively to equity growth.
- Dividend payments of 14,737,000 reduced retained earnings.
- Other factors decreased equity by 42,958,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €139.84 Million | +9.41% |
| Dividends Paid | €14.74 Million | -0.99% |
| Other Changes | €-42.96 Million | -2.89% |
| Total Change | €- | 5.85% |
Book Value vs Market Value Analysis
This analysis compares STEVANATO GROUP SPA O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.20x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.47x to 3.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.18 | €17.40 | x |
| 2022-12-31 | €3.76 | €17.40 | x |
| 2023-12-31 | €4.27 | €17.40 | x |
| 2024-12-31 | €5.15 | €17.40 | x |
| 2025-12-31 | €5.44 | €17.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently STEVANATO GROUP SPA O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.41%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.79%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.71x
- Recent ROE (9.41%) is below the historical average (12.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 15.95% | 15.92% | 0.59x | 1.68x | €50.11 Million |
| 2022 | 14.34% | 14.52% | 0.59x | 1.67x | €43.24 Million |
| 2023 | 12.86% | 13.42% | 0.52x | 1.83x | €32.38 Million |
| 2024 | 8.39% | 10.67% | 0.47x | 1.66x | €-22.66 Million |
| 2025 | 9.41% | 11.79% | 0.47x | 1.71x | €-8.81 Million |
Industry Comparison
This section compares STEVANATO GROUP SPA O.N.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $6,113,896,806
- Average return on equity (ROE) among peers: -4.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| STEVANATO GROUP SPA O.N. (87N) | €1.53 Billion | 15.95% | 0.69x | $1.01 Billion |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $4.13 Billion | 6.44% | 0.93x | $15.47 Billion |
| MEDIMI AB AK (79T) | $13.75 Million | -103.63% | 0.50x | $365.27K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-938.43K | 0.00% | 0.00x | $210.67K |
| Carl Zeiss Meditec AG (AFX) | $1.68 Billion | 14.09% | 0.43x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.06 Billion | 8.69% | 0.65x | $2.14 Billion |
| Bio-gate AG (BIG1) | $4.25 Million | -42.46% | 0.46x | $7.12 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $8.29 Billion | 56.75% | 3.52x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $38.15 Billion | 5.64% | 0.59x | $78.07 Billion |
About STEVANATO GROUP SPA O.N.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprisi… Read more